Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 14/20 | 0.48 |
| ▸ | DRD2 | P14416 | 10/20 | 0.45 |
| ▸ | HTR1A | P08908 | 6/20 | 0.44 |
| ▸ | HTR7 | P34969 | 4/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6743930 | 0.93 | HTR2A (0.48) | HTR2ADRD2HTR1AHTR7HTR6 | |
| SCHEMBL6748119 | 0.90 | HTR2A (0.45) | HTR2ADRD2HTR1AHTR7HTR6 | |
| SCHEMBL6750984 | 0.89 | HTR2A (0.56) | HTR2ADRD2HTR1AHTR7HTR6 | |
| SCHEMBL6748066 | 0.87 | HTR2A (0.47) | HTR2ADRD2HTR1AHTR7HTR6 | |
| SCHEMBL6220169 | 0.84 | HTR2A (0.53) | HTR2ADRD2HTR1AHTR7HTR6 | |
| SCHEMBL6220794 | 0.84 | HTR2A (0.49) | HTR2ADRD2HTR1AHTR7HTR6 | |
| SCHEMBL6748822 | 0.82 | HTR2A (0.49) | HTR2ADRD2HTR1AHTR7HTR6 | |
| SCHEMBL6744999 | 0.80 | HTR2A (0.57) | HTR2ADRD2HTR1AHTR7 | |
| SCHEMBL6224337 | 0.78 | HTR2A (0.70) | HTR2ADRD2HTR1A | |
| SCHEMBL6748898 | 0.76 | HTR2A (0.45) | HTR2ADRD2HTR1AHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138230-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | ANDREANA TONJA LYNN (US) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138230-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | CNR1, DRD2, CNR2 | HTR2A 16/4885DRD2 2/4885HTR1A 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.